Skip to main content

Table 3 Cost of hospitalization in the duration of treatment

From: Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)

 

Total

GRA

PALO

n = 43

n = 23

n = 20

Total medical cost (JPY)

mean

1,113,138.8

1,199,584.35

1,013,726.5

SD

870,137.9

1,043,255.9

627,690.9

range

371,080 - 4,801,680

371,080 - 4,801,680

529,060 - 2,839,830

Drug costs (JPY)

mean

195,716.7

227,712.6

158,921.5

SD

152,411.2

189,732.7

83,676.9

range

61,060 - 848,610

70,800 - 848,610

61,060 - 449,030

Regimen

CDDP + GEM

13

6

7

CDDP + PEM

5

4

1

CDDP + VP16

8

3

5

CDDP

5

3

2

CDDP + CPT

4

3

1

CDDP + DTX

6

3

3

CDDP + S1

2

1

1

Tumour type

NSCLC

25

12

13

SCLC

12

6

6

Cervical esophagus caner

1

1

0

Pharyngeal caner

4

3

1

Nasal caner

1

1

0

  1. Among 59 patients enrolled in TRIPLE study from the Cancer Institute Hospital, Japanese Foundation for Cancer Research, 43 patients were enabled to obtain the receipt information of hospitalization
  2. The cost data before 2011 on this facility had become unavailable by refurbishing the medical computer system, and accordingly among 59 patients enrolled in the TRIPLE study were used the data of 43 patients
  3. range = minimum to maximum
  4. CDDP: cisplatin, GEM: gemcitabine,PEM: pemetrexed, VP16: etoposide, CPT: irinotecan,
  5. DTX: docetaxel, S1: tegafur/gimeracil/oteracil
  6. NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer